


Services Include

- Design and Implementation of Medicinal Chemistry Programs
- Initiation and Management of CRO Activities
- Corporate Due Diligence
- IP Consulting
- Laboratory Design and Outfitting
- Custom Organic Synthesis



Founder Daniel E. Levy received his Ph.D. in organic chemistry from MIT and his B.S. degree from the University of California - Berkeley. Since 1992, Dr. Levy has worked with companies in capacities ranging from consultant to director. His broad experience in drug research and development provides him a unique perspective enabling him to address issues at the interface of chemistry and biology long before they impede progress.

DEL BioPharma
(650) 704-3051
del345@gmail.com
www.DELbiopharma.com



BioPharma

Consulting Services for
Drug Discovery Programs

Cut R&D costs and protect operating capital with DEL BioPharma

Expert oversight of drug discovery/development programs from lead identification to clinical

- **Design and Implementation of Medicinal Chemistry Programs**

- Efficient project planning
- Immediate program execution
- Reduced cost of laboratory services
- No need for committed overhead/infrastructure

- **Initiation and Management of CRO Activities**

- mg to multi kg GMP quantities
- Synthetic route design/selection
- Sourcing, RFP generation and vendor selection
- Effective technology transfer and oversight
- Project management and troubleshooting
- Well connected with both foreign and domestic CROs

- **Corporate Due Diligence**

- Third party evaluation of strategic and scientific viability

- **IP Consulting**

- Design and expansion of project-specific intellectual property
- Patent drafting services from claims to complete applications

- **Laboratory Design and Outfitting**

- **Custom Organic Synthesis**

"I highly recommend Dan Levy in support of organic chemistry projects. Dan took on our very difficult project and not only guided it to completion, he identified an analog that became our new lead compound saving us hundreds of thousands of dollars. Dan has proven to be an excellent contributor to our patent applications saving us thousands of dollars compared to a patent attorney. Dan has introduced us to and initiated discussions with potential investors and led our effort in CMC contributions including metabolite ID, polymorphs, formulations and radio labeling. Dan is inventive, trustworthy, punctual, well-organized, and he is an expert in his field. Dan is a pleasure to work with and he has brought great value to our company." – Mike Lewandowski, CSO at Prevacus

"Dan is a superb chemist who designs the chemistry approach based on the budget, i.e. more focused SAR for a small biotech and broader approach for an established company. In our case he was instrumental in both the design of the chemistry and synthetic steps as well as program management to make sure outsourced chemistry is done in a timely manner and serves as trouble shooter on problematic synthetic steps to facilitate progress. He understands composition of matter patents and can write most of the patent to reduce legal costs. In addition to his command of the field, he is personable and remarkably efficient so that cost is minimized." – Howard Schulman, President and CSO at Allosteros

"Daniel is a very creative and competent synthetic organic chemist, and he has demonstrated through this project to me and to my team his ability to move into a new area and adapt quickly to produce real results. I recommend him highly to anyone seeking a consulting chemist as a partner." - Steven Chamow, Senior Vice President at Intradigm Corporation

Medicinal chemistry strategies designed to proactively address:


- PK/ADME
- Formulation
- Toxicity
- Scale-up

Extensive experience targeting:

- Kinases
- GPCRs
- ADP receptors
- Matrix metalloproteinases
- Cell adhesion molecules

Organic chemistry expertise with multiple structural classes including:

- Sugars/glycomimetics
- Peptides/peptidomimetics
- Nucleosides
- Heterocycles
- Steroids
- PEGs
- Lipids



BioPharma

Consulting Services for
Drug Discovery Programs